The article discusses the potential of digital therapeutics (DTx) to enhance the effectiveness of pharmaceutical drugs and biological products for chronic diseases. DTx, defined as mobile medical apps authorized by regulatory bodies like the US Food and Drug Administration (FDA), can address limitations such as medication non-adherence, adverse effects, and inadequate efficacy. The integration of DTx with drugs and biologics follows the guidelines for drug-device combination products, offering personalized therapies for chronic conditions. Preclinical and clinical studies demonstrate that DTx can improve outcomes in various chronic diseases, including Alzheimer's disease, dementia, rheumatoid arthritis, cancer, chronic pain, depression, anxiety, and epilepsy. Digital interventions, such as mobile apps, virtual reality, and video games, have shown clinically meaningful benefits in improving patient outcomes, self-management, and quality of life. The article also highlights the potential of DTx in drug repurposing, gene therapies, and addressing the "patent cliff" issue, where existing drugs face competition from biosimilars. Overall, the integration of DTx with pharmacotherapies is expected to benefit patients, healthcare professionals, and the pharmaceutical industry by providing more effective and personalized treatments.The article discusses the potential of digital therapeutics (DTx) to enhance the effectiveness of pharmaceutical drugs and biological products for chronic diseases. DTx, defined as mobile medical apps authorized by regulatory bodies like the US Food and Drug Administration (FDA), can address limitations such as medication non-adherence, adverse effects, and inadequate efficacy. The integration of DTx with drugs and biologics follows the guidelines for drug-device combination products, offering personalized therapies for chronic conditions. Preclinical and clinical studies demonstrate that DTx can improve outcomes in various chronic diseases, including Alzheimer's disease, dementia, rheumatoid arthritis, cancer, chronic pain, depression, anxiety, and epilepsy. Digital interventions, such as mobile apps, virtual reality, and video games, have shown clinically meaningful benefits in improving patient outcomes, self-management, and quality of life. The article also highlights the potential of DTx in drug repurposing, gene therapies, and addressing the "patent cliff" issue, where existing drugs face competition from biosimilars. Overall, the integration of DTx with pharmacotherapies is expected to benefit patients, healthcare professionals, and the pharmaceutical industry by providing more effective and personalized treatments.